



medlab

MEDLAB CLINICAL LIMITED

ABN: 51 169 149 071

**APPENDIX 4E (RULE 4.3A)
PRELIMINARY FINAL REPORT
FOR THE YEAR ENDED 30 JUNE 2019**

For personal use only

RESULTS FOR ANNOUNCEMENT TO THE MARKET

CURRENT REPORTING PERIOD:
PREVIOUS CORRESPONDING PERIOD:

Financial Year Ended 30 June 2019
Financial Year Ended 30 June 2018

KEY INFORMATION	2019 \$	Up/Down	Movement
Revenue from ordinary activities	8,086,760	Up	46%
(Loss) from ordinary activities after tax attributable to members	(8,090,937)	Up	77%
Net (loss) attributable to members	(8,090,937)	Up	77%
	2019 \$		2018 \$
Dividends proposed	Nil		Nil
Net tangible assets per security	0.071		0.105

During the period, Medlab has made significant advances in both research and in commercial operations. A summary of recent achievements are:

- Revenue up by 46% (after discount and promotional costs) to \$8.1M
- Cash collections from customers up 24%
- NanaBis™ trial at Royal North Shore Hospital
 - Stage 1 completed – good encouraging data
 - Stage 2 95% completed
- NanaBis™ comparison to other approved Cannabis product shows superiority
- Depression Phase 2b trial progressing well – early data promising
- NanaBidual™ study completed – trial demonstrates safety, absorption and utilisation
- Nutraceutical business showing strong financial and distribution progression
- Partnering talks underway, either Heads of Agreements signed or in advanced discussions for:
 - NanaBis™ – global regions
 - NanoCBD – global regions
 - Nutraceuticals – US market

Medlab's net loss for the period has increased due to the costs incurred in accelerating the Company's research projects and the progression of the its commercial operations (namely the nutraceutical business as per recent announcements).

For a more detailed report of the company's operations, refer to the Chairman and CEO Reports in the 2019 Annual Report.

This report should be read in conjunction with the consolidated financial report of Medlab Clinical Limited for the year ended 30 June 2019 which has been audited by ESV Accounting and Business Advisors. An unqualified opinion has been issued by the auditor.



Sean Hall
Managing Director
Dated this 30th day of August 2019